TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03199040
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: -Human monoclonal antibody
Study: NCT00228995
Drug: epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00029692
Drug: Ginseng
Normalized name: Ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00029692
Drug: Ginkgo
Normalized name: Ginkgo
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00731783
Drug: 2% Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apply ointment to the anterior nares twice daily for 5 days.
Study: NCT00731783
Drug: 4% Chlorhexidine liquid soap
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bathe with liquid soap daily for 5 days.
Study: NCT02849678
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% Ropivacaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision. It is the local anesthetic used as the standard drug in paravertebral nerve blocks at our institution. It is also used in other nerve block infusions at our hospital and institutions across the country. It will be used as the standard drug to which lidocaine is compared.
Study: NCT05001074
Drug: Extended release tacrolimus
Normalized name: tacrolimus Extended Release Oral Tablet
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: de novo cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus direct post-lung transplantation Conversion cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus when \>1 year post-lungtransplantation and with stable graft function
Study: NCT00827606
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin tablets or chewable tablets, 5, 10, 20, 40 mg strengths, once daily, for three years (an 80 mg maximum daily dose is delivered by taking two 40 mg strengths, once daily)
Study: NCT01444248
Drug: Glimepiride/ Metformin
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4/1000mg once daily
Study: NCT01444248
Drug: Glimepiride/ Metformin
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4/1000mg bid
Study: NCT02849678
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision.~At a concentration of 0.5%, Lidocaine has been deemed safe to use for peripheral nerve blocks and analgesia. There are several studies to support this as listed in the references. Compared to ropivacaine, lidocaine is shorter-acting, less cardiotoxic, and safer to use.
Study: NCT01722604
Drug: brinzolamide 1% ophthalmic suspension
Normalized name: Brinzolamide 1% Ophthalmic Suspension
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: brinzolamide 1% ophthalmic suspension
Study: NCT04303130
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carelizumab: PD-1 antibody SHR-1210: SHR-1210 is administered by intravenous infusion, a fixed dose of 200 mg, and intravenous infusion over 30 minutes (the overall infusion time including the flushing time is not shorter than 20 minutes, not longer than 60 minutes), once every 3 weeks, continued medication until the disease progresses intolerable toxicity and receive immunotherapy for a maximum of 2 years (35 cycles); Endo: once a day, 7.5 mg / m2 intravenous infusion, continuous administration for 14 days, rest for a week (or the corresponding dose using a micro-micropump), continued medication until disease progression toxicity intolerance.~The combination regimen is a medication cycle every three weeks (21 days).
Study: NCT00648947
Drug: Clopidogrel Bisulfate Tablets 75 mg
Normalized name: Clopidogrel Bisulfate
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 75mg, single dose fasting
Study: NCT02895373
Drug: Alprostadil
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
Study: NCT02895373
Drug: 0.9% sodium chloride solution
Normalized name: Precedex 80mcg/20mL in 0.9% Sodium Chloride Solution for Injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
Study: NCT02078791
Drug: Botox infiltration
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: botox cervical infiltration in a group
Study: NCT01707043
Drug: Taclonex
Normalized name: Taclonex
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be evaluated at baseline, Day 3 and Day 6 (or end of study).
Study: NCT00112463
Drug: romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DEP is administered at a dose of 13 mg/m2 as a 4-hour intravenous infusion in the outpatient setting.
Study: NCT04601792
Drug: Individualized Decoction
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied in the Tested Drug Observation Period. It is the highly individualized treatment of TCM, the modification of Bronchiectasis Stabilization Decoction (Rhizoma Fagopyri Cymosi 30g, Radix Lithospermi 15g, Radix Ophiopogonis 15g, Poria cocos 15g, Radix Astragali 20g, Rhizoma Bletillae 10g, Platycodon grandiflorum 10g, Semen Coicis 30g) based on syndrome differentiation. For example, for patients with qi and yin deficiency syndrome, the investigators added Adenophora Root, Radix Glehniae and Radix Rehmanniae Recens etc. For patients with phlegm-heat syndrome, the investigators added Radix Scutellariae and Viola Yedoensis etc. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
Study: NCT00171886
Drug: Octreotide
Normalized name: Octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003630
Drug: arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00780494
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous 15 mg/kg
Study: NCT00780494
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 6, Intravenously Day 1 every 21 days
Study: NCT01870596
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02352259
Drug: Bleomycin PHC 15 e. (United States Pharmacopeia - USP)
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous in bolus administration of bleomycin (15 mg/m2), 8 minutes before application of electric pulses
Study: NCT01870596
Drug: CHK1 Inhibitor SCH 900776
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00362765
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 160 mg
Study: NCT01056510
Drug: bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 90mg/m2 (first-line) or 70mg/m2 (second-line) iv, days 1 and 2 every 4 weeks, cycles 1-6
Study: NCT01056510
Drug: chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg/m2 po days 1-7 every 4 weeks, for up to 12 cycles
Study: NCT01056510
Drug: rituximab [MabThera/Rituxan]
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375mg/m2 iv day 1 of cycle 1, followed by 500mg/m2 iv every 4 weeks cycles 2-6
Study: NCT01382797
Drug: ALKS 37
Normalized name: ALKS 29
DrugBank: ALKS 29 (DB05723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral administration
Study: NCT00362765
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2000 mg
Study: NCT00612287
Drug: buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sublingual buprenorphine; product name Suboxone® (buprenorphine/naloxone). Dosing is informed by a clinical guideline which permits flexibility dependent up physician's clinical judgment. During the induction period (Day 1, at the physician's office) the first dose is 2 mg and can be brought up to 20 mg depending on patient's response. On Day 2 going forward dose can range from 2 mg q8h to 12 mg q8h. Rescue doses with buprenorphine are also permitted.
Study: NCT00537979
Drug: Paricalcitol injection
Normalized name: paricalcitol Injection
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Most recent iPTH level in pg/mL divided by 100 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly
Study: NCT00537979
Drug: Paricalcitol capsules
Normalized name: Paricalcitol Capsules
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Most recent iPTH level in pg/mL divided by 80 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly
Study: NCT00868374
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
Study: NCT04259281
Drug: GTX-102
Normalized name: GTX-102
DrugBank: GTX-102 (DB16981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: antisense oligonucleotide
Study: NCT00064974
Drug: CC-5013
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-5013 10 mg (two 5 mg capsules) daily on days 1-28 every 28 days (28 day cycles)
Study: NCT02009163
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SDP489 30, 50, or 70mg capsule once per day (open-label and double-blind periods)
Study: NCT03328676
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
Study: NCT03305263
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet a day from inclusion until end of pregnancy or gestational age 28
Study: NCT03305263
Drug: Hydroxychloroquine placebo
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet a day from inclusion until end of pregnancy or gestational age 28
Study: NCT00652288
Drug: Insulin analogs (Lispro and Aspart)
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin bolus given through insulin pump
Study: NCT00652288
Drug: Insulin analogs (Aspart and Detemir)
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drugs given separately
Study: NCT00652288
Drug: Insulin analogs (Aspart and Detemir)
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drugs given in the same injection
Study: NCT00725803
Drug: GS-9450
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-9450 capsules administered orally once daily
Study: NCT02002754
Drug: Bambuterol Hydrochloride tablets
Normalized name: bambuterol
DrugBank: Bambuterol (DB01408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol Hydrochloride tablets(10mg) 3 tablets qd for three days(swallowed by warm water at 0.5-1h after each meal)
Study: NCT02453386
Drug: tozadenant
Normalized name: Tozadenant
DrugBank: Tozadenant (DB12203)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01926821
Drug: Sonifilan
Normalized name: Sonifilan
DrugBank: Sizofiran (DB13128)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonifilan inj 20mg Intra muscular injection, twice per week for 8 weeks, total 16 times
Study: NCT00560443
Drug: tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2,5 mg/ kg per os in one dose
Study: NCT01665209
Drug: Morphine Sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine Sulfate 60mg Extended-release tablets
Study: NCT00589420
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00589420
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02798055
Drug: Bosentan group
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00927290
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone, 45 mg QD (30 mg QD the first month)
Study: NCT02272647
Drug: Oral Micronized Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02272647
Drug: Ghrelin (0.3 ug/kg)
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02272647
Drug: Medroxyprogesterone - Acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00053963
Drug: romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01431976
Drug: Lamictal
Normalized name: Lamictal
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No comparison
Study: NCT01718496
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient with advanced COPD will randomly receive single dose Morphine to assess its effect on dyspnea and exercise tolerance
Study: NCT00253227
Drug: galantamine hydrobromide
Normalized name: Galantamine Hydrobromide
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02082392
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03840291
Drug: Edoxaban
Normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Edoxaban will be used for resolution of left atrial appendage thrombi
Study: NCT02777372
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline will be provided at a dose of 50 mg daily for up to 3 weeks, depending on the length of a woman's luteal phase. Medication will be taken only during the luteal phase. Women will initiate sertraline treatment upon determining that they have ovulated (using a urine luteinizing hormone (LH) Kit) and remain on sertraline until onset of their next menstrual period at which time they will stop taking the medication.
Study: NCT02755714
Drug: Ipratropium bromide spray
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will - or will not - receive Ipratropium bromide spray (MDI) 20 μg given through a plastic spacer two puffs 1 hour before a continuous laryngoscopy exercise test (CLE-test)
Study: NCT01547169
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10IU of insulin detemir, administered intranasally twice per day for a 3 week duration
Study: NCT01547169
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20IU insulin detemir, administered intranasally twice per day for a 3 week duration
Study: NCT00841568
Drug: OPC-41061
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally administered at 15 mg twice daily (morning and evening) for a maximum of 3 years.
Study: NCT01022242
Drug: PXL01
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PXL01 is a synthetic peptide sequentially derived from human lactoferrin. PXL01 is formulated in a viscous solution of sodium hyaluronate. The drug product is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
Study: NCT00030186
Drug: CEP-701 60mg
Normalized name: CEP-9722
DrugBank: CEP-9722 (DB14882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mg orally 2 times a day for 28 days
Study: NCT00030186
Drug: Cep-701 80mg
Normalized name: CEP-9722
DrugBank: CEP-9722 (DB14882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80mg 2 times a day, dependent upon response to cycle 1
Study: NCT00030186
Drug: Cep-701 40mg
Normalized name: CEP-9722
DrugBank: CEP-9722 (DB14882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg 2 times a day, dependent upon response to cycle 1
Study: NCT00004132
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004132
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01471171
Drug: Aclidinium Bromide
Normalized name: Aclidinium Bromide
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 puff of 400 micro grams in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
Study: NCT00810004
Drug: Ferinject
Normalized name: epinephrine
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion of iron
Study: NCT03300674
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone intravenous infusion
Study: NCT03300674
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine intravenous infusion
Study: NCT03801980
Drug: SK-1403
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
Study: NCT02336659
Drug: exendin 9-39
Normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exendin 9-39 is a specific GLP-1 receptor antagonist
Study: NCT02336659
Drug: sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DPP-4 Inhibition
Study: NCT01857284
Drug: Tauroursodeoxycholic Acid Capsules
Normalized name: Tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg.tid.po
Study: NCT01857284
Drug: Ursodeoxycholic Acid Capsules
Normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg.tid.po
Study: NCT01055600
Drug: eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.
Study: NCT01033825
Drug: Ciclesonide HFA Nasal Aerosol 320 mcg
Normalized name: Ciclesonide Nasal Aerosol
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide HFA Nasal Aerosol 320 μg once daily
Study: NCT01033825
Drug: Ciclesonide HFA Nasal Aerosol 160 mcg
Normalized name: Ciclesonide Nasal Aerosol
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide HFA Nasal Aerosol 160 μg once daily
Study: NCT01033825
Drug: Ciclesonide Aqueous Nasal Spray 200 mcg
Normalized name: ciclesonide Metered Dose Nasal Spray
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide Aqueous Nasal Spray 200 mcg once daily
Study: NCT01033825
Drug: Placebo plus Dexamethasone HFA
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone capsules 6 mg once daily
Study: NCT01033825
Drug: Placebo AQ plus Dexamethasone 6 mg
Normalized name: dexamethasone 6 MG
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo AQ plus Dexamethasone 6 mcg capsules once daily
Study: NCT01550146
Drug: Dexamethasone acetate
Normalized name: Dexamethasone Acetate
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: iv. dexamethasone 0.1 mg/kg
Study: NCT01328951
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib will be administered as 150 mg PO once daily until disease progression, death, or unacceptable toxicity, as first-line maintenance or as second-line therapy for those who progress while receiving placebo.
Study: NCT02836028
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib monotherapy 1mg/day orally
Study: NCT02836028
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: temozolomide 37.5 mg/m2 on days 1-5 of each cycle
Study: NCT02319187
Drug: S1
Normalized name: LS11
DrugBank: LS11 (DB05918)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S1 80mg to 120 mg per day on Days 1-14, every 21 days
Study: NCT02319187
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: S1 80mg to 120 mg per day on Days 1-10, every 14 days;
Study: NCT02319187
Drug: irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: irinotecan 160mg/m2 d1, every 14 days
Study: NCT01553136
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then two 0.5 mg tablets (1 mg) twice per day